Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices

References

• ACHEAMPONG, A. A., CHIEN, D.-S., LAM, S., VEKICH, S., BREAU, A., USANSKY, J., HARCOURT, D., MUNK, S. A., NGUYEN, H., GARST, M. and TANG-Liu, D., 1996, Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica, 26, 1035–1055.
   Google Scholar
• ANDERSSON, T. B., SJOBERG, H., HOFFMANN, K.-J., BOOBIS, A. R., WATTS, P., EDWARDS, R. J., LAKE, B. G., PRICE, R. J., RENWICK, A. B., GômEz-LEcHôN, M. J., CASTELL, J. V., INGELMAN-SUNDBERG, M., HIDESTRAND, M., GOLDFARB, P. S., LEWIS, D. F. V., CORCOS, L., GUILLOUZO, A., TAAVITSAINEN, P. and PELKONEN, O., 2001, An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metabolism and Disposition, 29, 712–720.
   Google Scholar
• BEAMAND, J. A., PRICE, R. J., CUNNINGHAME, M. E. and LAKE, B. G., 1993, Culture of precision-cut liver slices: effect of some peroxisome proliferators. Food and Chemical Toxicology, 31, 137–147.
   PubMed Web of Science ®Google Scholar
• BEER, B., IENI, J. R., Wu, W.-H., CLODY, D., AMORUSI, P., ROSE, J., MANT, T., GAUDREAULT, J., CATO, A. and STERN, W., 1994, A placebo-controlled evaluation of single, escalating doses of CL-284,846, a non-benzodiazepine hypnotic. Journal of Clinical Pharmacology, 34, 335–344.
   Google Scholar
• CHAUDHARY, I., DEMALO, W. and KANTROWITZ, J., 1994, Species comparison of in vitro and in vivo metabolism of CL- 284,846, a non- benzo diazepine sedative/hypnotic agent. Pharmaceutical Research, 11, S391.
   Google Scholar
• CLARKE, S. E., 1998, In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167-1202. CORNISH-BOWDEN, A., 1974, A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochemical Journal, 137, 143–144.
   Google Scholar
• DIXON, M., 1953, The determination of enzyme inhibitor constants. Biochemical Journal, 55, 170–171.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B. and CARLILE, D. J., 1997, Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metabolism Reviews, 29, 891–922.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B. and KENWORTHY, K. E., 2000, In vitro—in vivo scaling of CYP kinetic data not consistent with the classical Michaelis—Menten model. Drug Metabolism and Disposition, 28, 246–254.
   PubMed Web of Science ®Google Scholar
• KAWASHIMA, K., Hosoi, K., NARUKE, T., SHIBA, T., KITAMURA, M. and WATABE, T., 1999, Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metabolism and Disposition, 27, 422–428.
   PubMed Web of Science ®Google Scholar
• LAKE, B. G., 1987, Preparation and characterisation of microsomal fractions for studies of xenobiotic metabolism. In K. Snell and B. Mullock (eds), Biochemical Toxicology: A Practical Approach (Oxford: IRL Press), pp. 183–215.
   Google Scholar
• LAKE, B. G., BALL, S. E., KAD, J., RENWICK, A. B., PRICE, R. J. and SCATINA, J. A., 2002, Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica, 32, 835–847.
   PubMed Web of Science ®Google Scholar
• LIN, J. H. and Lu, A. Y. H., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361–390.
   PubMed Web of Science ®Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FAR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• PELKONEN, O., MYLLYNEN, P., TAAVITSAINEN, P., BOOBIS, A. R., WATTS, P., LAKE, B. G., PRICE, R. J., RENWICK, A. B., GOmEz-LEcoON, M.-J., CASTELL, J. V., INGELMAN-SUNDBERG, M., HIDESTRAND, M., GUILLOUZO, A., CORCOS, L., GOLDFARB, P. S. and LEWIS, D. F. V., 2001, Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica, 31, 321–343.
   Google Scholar
• RASHIDI, M. R., SMITH, J. A., CLARKE, S. E. and BEEDHAM, C., 1995, Inhibition of human and guinea-pig liver aldehyde oxidases in-vitro. Journal of Pharmacy and Pharmacology, 47, 1090.
   Google Scholar
• RENWICK, A. B., MISTRY, H., BALL, S. E., WALTERS, D. G., KAO, J. and LAKE, B. G., 1998, Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica, 28, 337–348.
   PubMed Web of Science ®Google Scholar
• ROBERTSON, I. G. C. and BLAND, T. J., 1993, Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochemical Pharmacology, 45, 2159–2162.
   Google Scholar
• RODRIGUES, A. D., FERRERO, J. L., AMANN, M. T., ROTERT, G. A., CEPA, S. P., SURBER, B. W., MACHINIST, J. M., TICH, N. R. SULLIVAN, J. P., GARVEY, D. S. FITZGERALD, M. and ARNERIC, S. P., 1994, The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, Cynomolgus monkeys, and humans. Drug Metabolism and Disposition, 22, 788–798.
   PubMed Web of Science ®Google Scholar
• ROSEN, A. S., FOURNIE, P., DARWISH, M., DANJOU, P. and TROY, S. M., 1999, Zaleplon pharmacokinetics and absolute bioavailability. Biopharmaceutics and Drug Disposition, 20, 171–175.
   PubMed Web of Science ®Google Scholar
• SMITH, S. R. and KENDALL, M. J., 1988, Ranitidine versus cimetidine: a comparison of their potential to cause clinically important drug interactions. Clinical Pharmacokinetics, 15, 44–56.
   PubMed Web of Science ®Google Scholar
• SOMOGYI, A. and MUIRHEAD, M., 1987, Pharmacokinetic interactions of cimetidine 1987. Clinical Pharmacokinetics, 12, 321–366.
   PubMed Web of Science ®Google Scholar
• STEENSMA, A., BEAMAND, J. A., WALTERS, D. G., PRICE, R. J. and LAKE, B. G., 1994, Metabolism of coumarin and 7-ethoxycoumarin by rat, guinea pig, Cynomolgus monkey and human precision-cut liver slices. Xenobiotica, 24, 893–907.
   PubMed Web of Science ®Google Scholar
• TANAKA, E., 1998, Clinically important pharmacokinetic drug—drug interactions: role of cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics, 23, 403–416.
   PubMed Web of Science ®Google Scholar
• UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370–381.
   PubMed Web of Science ®Google Scholar
• WORBOYS, P. D., BRADBURY, A. and HOUSTON, J. B., 1997, Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. Drug Metabolism and Disposition, 25, 460–467.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharmaceutical Research, 11, 921–924.
   PubMed Web of Science ®Google Scholar
• WU, W. H., Dicioccio, A. T., DEMAIO, W., AMORUSI, P., TONELLI, A. P. and MAYER, P. R., 1996, Mass balance and pharmacokinetics of zaleplon, a non-benzodiazepine sedative/hypnotic, in man. Pharmaceutical Research, 13, S487.
   Google Scholar